This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kida A, McDonald GB . Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol 2012; 49: 43–58.
Nojkov B, Signori C, Konda A, Fontana RJ . Lenalidomide-associated hepatotoxicity – a case report and literature review. Anticancer Res 2012; 32: 4117–4120.
Zanella M-C, Rubbia-Brandt L, Giostra E, Chalandon Y, Hadengue A, Spahr L . A case of drug-induced hepatitis due to lenalidomide. Case Rep Gastroenterol 2011; 5: 217–222.
Hussain S . Lenalidomide-induced severe hepatotoxicity. Blood 2007; 110: 3814.
Vilas-Boas F, Gonclaves R, Sobrinho SM, Lopes J, Macedo G . Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterol Hepatol 2012; 35: 560–566.
Shpall EJ . Lenalidomide-induced graft-vs-leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk 2014; 14: e105–e109.
Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118: 2413–2419.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. Exp Hematol 2013; 41: 134–142.
Coman T, Bachy E, Michallet M, Socié G, Uzunov M, Bourhis JH et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica 2013; 98: 776–783.
Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013; 3: e143.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Pauff, J., Gonzalez, R., Sajnani, K. et al. Post-allograft pomalidomide and reversible hepatotoxicity. Bone Marrow Transplant 49, 1341–1342 (2014). https://doi.org/10.1038/bmt.2014.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.128
This article is cited by
-
Pomalidomide
Reactions Weekly (2015)